Sight Sciences Inc (SGHT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sight Sciences Inc (SGHT) has a cash flow conversion efficiency ratio of -0.136x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.72 Million) by net assets ($64.29 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Sight Sciences Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Sight Sciences Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Sight Sciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sight Sciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sight Sciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SilverBox Corp V
NYSE:SBXE
|
-0.001x |
|
enCore Energy Corp. Common Shares
NYSE MKT:EU
|
-0.073x |
|
TruBridge Inc.
NASDAQ:TBRG
|
0.075x |
|
Western New England Bancorp Inc
NASDAQ:WNEB
|
0.023x |
|
Linhai Co Ltd
SHG:600099
|
0.432x |
|
Xuchang Ketop Testing Research Ins
SHE:003008
|
0.026x |
|
Singaraja Putra
JK:SINI
|
0.040x |
|
Nongshim Holdi
KO:072710
|
0.015x |
Annual Cash Flow Conversion Efficiency for Sight Sciences Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Sight Sciences Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see Sight Sciences Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $87.52 Million | $-22.35 Million | -0.255x | +34.94% |
| 2023-12-31 | $120.22 Million | $-47.18 Million | -0.392x | +17.29% |
| 2022-12-31 | $160.08 Million | $-75.97 Million | -0.475x | -109.65% |
| 2021-12-31 | $232.11 Million | $-52.54 Million | -0.226x | -162.51% |
| 2020-12-31 | $-88.85 Million | $-32.17 Million | 0.362x | -20.78% |
| 2019-12-31 | $-54.68 Million | $-25.00 Million | 0.457x | -8.54% |
| 2018-12-31 | $-28.96 Million | $-14.47 Million | 0.500x | -- |
About Sight Sciences Inc
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases. The company operates in two segments, Surgical Glaucoma and Dry Eye. Its products include OMNI surgical system, an implant-free, handheld, single-use, therapeutic technology that enables ophthalmic surgeo… Read more